Quantcast

Latest Ziprasidone Stories

2012-02-23 18:00:25

Research: Differential risk of death in older nursing home residents prescribed specific antipsychotic medications: Population-based cohort study Nursing home residents over the age of 65 who take certain antipsychotic medication for dementia are at an increased risk of death, suggests a research paper published today on bmj.com. The Harvard Medical School study, the largest ever undertaken among US nursing home residents, looked at 75,445 older nursing home residents from 45 US states...

2010-11-12 13:09:15

Findings indicate two drugs of same class carry no difference in risk of mortality, a help for prescribing physicians The potential for harmful side effects associated with anti-psychotic medications for treating schizophrenia is a frustration for mental-health professionals who must balance this with the positive benefits of drugs. For example, the issue of the antipsychotic drug ziprasidone lengthening the QTc interval, a possible indicator of life-threatening heart arrhythmias, has...

2009-11-05 07:00:00

WALTHAM, Mass., Nov. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that widespread generic erosion of branded atypical antipsychotics will cause the bipolar disorder drug market to decline from $6.3 billion in 2008 to approximately $5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The new Pharmacor report entitled Bipolar Disorder finds that the...

2009-09-02 09:48:00

PHILADELPHIA, Sept. 2 /PRNewswire/ -- Pfizer, Inc. announced today it has agreed to plead guilty to criminal conduct and to pay more than $2 billion in criminal and civil fines, penalties and damages to settle allegations made in multiple whistleblower lawsuits that the pharmaceutical giant defrauded Medicare, Medicaid and other government-funded health care programs in connection with its market practices for four of its drugs. The settlement is the largest qui tam settlement in U.S....

bd11f4ae31c913548199ad9644300111
2009-09-02 10:30:00

The U.S. Department of Justice said pharmaceutical giant Pfizer will pay a record $2.3 billion fine to settle fraudulent marketing of the painkiller Bextra. Bextra was pulled off the market in 2005. The case settled Wednesday involved Pfizer's marketing of the drug for uses not approved by the Food and Drug Administration. A company must specify the intended use of a product, the Department of Health and Human Services said in a release. Once approved, the drug may not be marketed or promoted...

d4e2a612837dd6de7ccdeebd181ed5981
2009-06-05 14:48:00

The US Food and Drug Administration announced on Friday that it is investigating the approval of three popular antipsychotic drugs for children. The three drugs, currently marketed for adult use by AstraZeneca, Pfizer and Eli Lilly and Co, appear to be beneficial in children and adolescents, but FDA regulators said they must determine if the drugs pose a greater risk to younger patients. An agency panel is set to meet next week in order to weigh the risks of the psychiatric drugs in children...

2009-05-06 17:37:00

ROCKVILLE, Md., May 6 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that the US Food and Drug Administration (FDA) has granted marketing approval of Fanapt(TM) (iloperidone) for the acute treatment of adult patients with schizophrenia. The approval was supported by two placebo-controlled Phase III clinical studies comparing Fanapt(TM) to placebo and active control in patients with schizophrenia, as well as safety data from more than 3,000 patients....

2008-10-03 12:00:27

Orexigen Therapeutics, a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, has initiated its first Phase IIa clinical trial with OREX-003, a proprietary sustained release formulation of zonisamide plus olanzapine. The Phase IIa clinical trial, OZ-101, is designed to examine the effectiveness of OREX-003 in mitigating drug-associated weight gain or other metabolic consequences commonly experienced by patients taking atypical...

2008-07-30 09:01:27

Vanda Pharmaceuticals has received a not approvable letter from the FDA in response to its new drug application for iloperidone, an investigational atypical antipsychotic that was reviewed for the treatment of schizophrenia. The FDA stated that Vanda had demonstrated the effectiveness of iloperidone at 24mg/day in the 3101 study for which the company reported results in December 2006, and that the efficacy was similar to the active comparator, ziprasidone (Geodon, Pfizer). In addition,...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.